Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of YD0293 in Healthy Subjects
NCT07098091Phase 1Enrolling by invitation
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of YD0293 in bronchiectasis and rhinosinusitis (6 arms), sponsored by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. Primary endpoint: Safety and Tolerability. Started Feb 2025; status: enrolling by invitation.
02
Drugs
YD0293
03
Conditions
bronchiectasisrhinosinusitis
Beyond the preview
Go deeper on NCT07098091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07098091.